Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Merck & Co., Inc.

MRK

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Last trade $143.46
Day change -$1.005 (-0.70%)
Day range $142.37 – $145.05
Volume 3,761,704
Market cap $356.13B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$356.13B
Price / earnings
145.18×
Price / book
7.93×
Price / sales
5.29×
EV / sales
5.94×
EV / EBITDA
29.56×

Profitability

Earnings per share
$1.00
Return on assets
1.85%
Return on equity
5.46%
Dividend yield
2.35%

Liquidity and leverage

Debt / equity
1.2×
Current ratio
1.35×
Quick ratio
1.14×
Cash ratio
0.33×

Cash flow

Price / cash flow
19.04×
Price / free cash flow
24.15×
Free cash flow
$14.75B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MRK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$18.09B$16.61B$16.29B$16.4B$17.28B$15.81B$15.53B$15.62B
Cost of revenue$4.89B$4.4B$4.2B$5.55B$3.86B$3.56B$3.42B$3.83B
Gross profit$13.19B$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.8B
Selling, general and administrative$2.89B$2.9B$2.7B$2.9B$2.63B$2.65B$2.55B$2.86B
Research and development$4.54B$9.74B$12.59B$3.89B$4.23B$4.05B$3.62B$4.58B
Total operating expenses$7.61B$12.8B$15.49B$7B$6.91B$7.26B$6.24B$7.5B
Operating income$5.59B-$584M-$3.4B$3.85B$6.51B$4.99B$5.87B$4.3B
Interest expense-$546M-$525M$0$0-$327M-$305M$0$0
Income before taxes$5.56B-$683M-$3.53B$3.42B$6.75B$5B$5.9B$4.17B
Income taxes$492M$654M$709M$458M$958M$571M$818M$426M
Net income$5.07B-$1.34B-$4.24B$2.96B$5.79B$4.43B$5.09B$3.74B
Net income attributable to common shareholders$5.07B-$1.34B-$4.24B$2.96B$5.79B$4.43B$5.08B$3.74B
EBITDA$7.55B$1.15B-$1.69B$6.53B$7.71B$6.67B$7.04B$5.55B
Basic earnings per share$2.05-$0.54-$1.72$1.19$2.32$1.76$2.01$1.48
Diluted earnings per share$2.04-$0.54-$1.72$1.19$2.32$1.76$2.01$1.48

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight

Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.

GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.

Zacks Investment Research

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.

The Motley Fool

Is Merck's Stock Still a Good Buy at $150?

Merck's stock has surged nearly 40% in 2026, driven by strong Keytruda revenue including its new subcutaneous formulation Keytruda Qlex. However, the analyst recommends holding off on buying at current levels due to upcoming patent expirations in 2028 and uncertain revenue outlook, despite the stock trading at a modest discount to the S&P 500 average P/E multiple.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 15, 2026$0.85Oct 7, 2026recurring
Jun 15, 2026$0.85Jul 8, 2026recurring
Mar 16, 2026$0.85Apr 7, 2026recurring
Dec 15, 2025$0.85Jan 8, 2026recurring
Sep 15, 2025$0.81Oct 7, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.